Manipal Journal of Medical Sciences
Abstract
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition. The patients of this disorder have impaired communication, and repetitive stereotypical atypical behavior with restricted interests and social behavior. Autism is not a single disease. It includes a spectrum of conditions. All types of seizures can be noted in epileptic seizures in people with ASD, the most common being focal seizures. Other types of seizures seen frequently include generalized seizures, absence seizures, etc. Commonly these children respond well to valproate, lamotrigine or levetiracetam. Perampanel (PER) is a noncompetitive antagonist of the a-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor. It is approved for the treatment of focal onset seizures and treatment of drug-resistant generalized seizures. Only a few reports have been found of the use of Perampanel in patients with Autism and Epilepsy, and these use Perampanel as an add-on therapy. We hereby report this case in which the child with ASD, previously on multiple medications, had his seizures controlled on monotherapy with Perampanel.
Recommended Citation
Mittal, Saumya and Issar, Hompriya
(2022)
"Perampanel: A Monotherapy in Drug Resistant Epilepsy in Autism Spectrum Disorder,"
Manipal Journal of Medical Sciences: Vol. 7:
Iss.
2, Article 2.
Available at:
https://impressions.manipal.edu/mjms/vol7/iss2/2
